Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin Dosed by Weight or Kidney Function in Adults With Obesity
NCT06601257Phase 1Completed
- Sponsor
- University of Michigan
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vancomycin in bacterial infection (2 arms), sponsored by University of Michigan. Primary endpoint: Probability of target attainment at 24 hours. Started Apr 2025; status: completed.
02
Drugs
vancomycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06601257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06601257.